Stockchase Opinions

The Weekly Buzzing Stocks by Billy Kawasaki AbbVie Inc. ABBV-N TOP PICK May 16, 2024

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis. Social media mentions are up 400% in the past 24h.

$163.835

Stock price when the opinion was issued

0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY

Have a great drug pipeline.

BUY

Management has replaced key drug, Humira, and made key acquisitions. Are doing all the right things.

BUY

They beat top and bottom and raised guidance. A nice quarter. Their key drugs were way up. They have a strong pipeline.

PAST TOP PICK
(A Top Pick Dec 01/23, Up 45%)

Is one of the largest companies in bio-medicals. Growth has been impressive. Are expanding into neuro-science, Alzheimer's. They clearly replaced a key drug going off-patent with a good pipeline. Two anti-inflammatory drugs are outperforming expectations.

BUY ON WEAKNESS

He added more AbbVie. Obviously, today's news about the disappointing drug trials is not good. This schizophrenia drug was projected to make $1.1 billion in sales four years from now. But today's share plunge is too great, overdone. He might add on even more weakness. Trades at 14x forward PE and pays a 3.9% dividend. It's a great company on sale. They have a long track record of making acquisitions.

WEAK BUY

The drug companies are in the dog house. If you buy this, you must be patient. It yields 4%.

TOP PICK

It is a large cap biotech with a temporary pullback. Humera went off patent so there are some declines in revenue. He really likes the re-iteration of Humera which has taken off. Also it is re-designing a mistrial.          Buy 20  Hold 10  Sell 0

(Analysts’ price target is $203.96)
BUY

His best performer so far this year, up 12%. Well-managed. They replaced Humira with hit drugs and added key companies; pays a 3.2% dividend. 

BUY

Skyrizi continues to work.

PARTIAL BUY

Has no patent cliff. They have great franchises in oncology, immunology and others. Shares are down because bond yields are rising. Dividend pays only 3.7%, below interest rates. That said, good to start a position now given their drugs, including Botox.